NeoGenomics Earnings Call Signals Growth With Caveats

NeoGenomics Inc. ((NEO)) has held its Q4 earnings call. Read on for the main highlights of the call.

NeoGenomics Inc. struck an optimistic tone on its latest earnings call, pairing record 2025 revenue and accelerating clinical and NGS growth with a confident 2026 outlook. Management acknowledged ongoing margin and reimbursement headwinds, but emphasized a deliberate pivot toward higher‑value testing, productivity gains and commercial expansion to turn growth into stronger cash generation.

Record Revenue and Broad-Based Growth

NeoGenomics posted full‑year 2025 revenue of $727.0 million, up 10% from 2024, with fourth‑quarter revenue rising 11% year over year to $190.0 million. The performance underscored resilient demand despite portfolio changes and macro noise, positioning the company as a steady growth story in oncology diagnostics.

Clinical Business Delivers Double-Digit Gains

Clinical revenue was the main engine, growing 15% for the year and 16% in Q4, even 13% for the year when excluding the Pathline acquisition. Management highlighted that both higher volumes and better average unit price (AUP) drove the gains, reflecting success in moving toward more complex, higher‑value tests.

NGS Outperformance and Mix Shift

Next‑generation sequencing continued to outpace the broader business, with NGS revenue up 23% year over year in Q4 and now about one‑third of clinical revenue. Five NGS products launched in 2023 already contributed 23% of clinical revenue in Q4, underscoring the rapid shift of the portfolio toward advanced molecular testing.

Profitability Improving Despite Headwinds

Adjusted gross profit increased by $5.8 million, or 7%, in Q4, and adjusted EBITDA climbed 10% to $13.4 million, with full‑year adjusted EBITDA up 9% to $43.4 million. Management framed this as proof that the model can generate leverage, even as new product launches and acquisitions temporarily weigh on margins.

Volume Momentum and Same-Store Strength

Public test volumes rose 11% in Q4, reflecting healthy underlying demand across the core franchise. Same‑store revenue excluding Pathline hit $170.0 million in the quarter, up 14% year over year on a 6% increase in volumes and 7% AUP growth, signaling balanced growth rather than discount‑driven gains.

Commercial Execution and Customer Loyalty

Customer satisfaction remained a standout, with a Net Promoter Score of 79 and further improvement in 2025, indicating deep loyalty among clinicians. The number of pathologists and oncologists ordering five or more tests grew 14%, and roughly 40% of active providers now order at that level, expanding NeoGenomics’ high‑value user base.

Strategic Launches and Reimbursement Progress

The RADAR ST bridging study delivered 97% concordance with the prior RADAR assay and secured reimbursement for certain head and neck and breast cancer indications, with full clinical launch slated by month‑end. PanTracer tissue volumes nearly doubled year over year and the new PanTracer Pro offering was introduced, broadening the precision oncology toolkit.

Expanding Commercial Capacity

To support RADAR ST and PanTracer, NeoGenomics has invested heavily in its salesforce, adding 35 oncology specialists in late 2024 and 2025. The company plans to add more than 25 additional oncology sales specialists by the third quarter of 2026, aiming to convert pipeline interest into measurable test volume and revenue.

Nonclinical Revenue Drag

Nonclinical revenue remained a clear weak spot, declining more than 25% in Q4 and 24% for the full year. Management has baked this softness into the 2026 outlook, acknowledging that the segment will continue to pressure margins even as the clinical business grows.

Gross Margin Compression and Launch Costs

Adjusted gross margin for 2025 came in around 46%, down 111 basis points from the prior year, reflecting Pathline‑related mix, nonclinical weakness and the cost of launching clinical liquid biopsy offerings. Leadership argued that these investments are front‑loaded and should set the stage for margin recovery as volumes scale.

Deliberate Volume Rationalization

The company intentionally reduced exposure to high‑volume, low‑value accounts, which weighed on sequential volume trends in Q4. This strategy is shifting the business toward a lower‑volume, higher‑AUP mix, intended to support long‑term profitability even if short‑term reported volumes appear softer.

Pharma Revenue Weakness and Timing Risk

Pharma‑related revenue, while only about 5%–6% of the total, is expected to decline in the mid‑ to upper single‑digit range in 2026 before returning to growth in 2027. Management sees this as a manageable but real headwind, highlighting that the core investment thesis rests far more on clinical diagnostics than pharma services.

Reimbursement Timing Remains an Unknown

There is still uncertainty around reimbursement timing for PanTracer liquid and additional RADAR ST indications, and the 2026 guide assumes only modest contributions in the back half. Faster reimbursement decisions could provide upside to revenue and profit, but management chose not to rely on that in its base case.

Modest but Positive Cash Generation

Operating cash flow stayed slightly positive at $1.0 million in Q4 and $5.0 million for the full year, contributing to more than 35% improvement in free cash flow versus 2024. Cash on hand ended Q4 at $160.0 million, giving the company room to fund launches while targeting sustained free‑cash‑flow positivity in 2026.

Multi-Year LIMS Consolidation

NeoGenomics is migrating from eight separate LIMS platforms to a single system, a multi‑year project designed to streamline operations and improve margin. Management cautioned that the most meaningful efficiency gains are expected from 2027 onward, so investors should not expect a near‑term boost from this initiative.

Weather-Related Volatility in Early 2026

The company flagged that extreme weather could dampen Q1 2026 test volumes and revenue, a factor already incorporated into guidance. While seen as transitory, this adds a layer of execution risk early in the year that investors will watch closely as results come in.

2026 Outlook and Financial Targets

For 2026, NeoGenomics guided revenue to $793 million–$801 million, about 10% growth at the midpoint, and adjusted EBITDA of $55 million–$57 million, implying roughly 27%–31% growth. The company expects about 100–120 basis points of gross margin improvement, a back‑half weighting of RADAR ST, PanTracer and Pathline, and aims to turn free‑cash‑flow positive while maintaining a strong cash position.

NeoGenomics’ latest call painted a picture of a company leaning into higher‑value oncology testing, NGS innovation and commercial expansion while managing through nonclinical and pharma softness. For investors, the key takeaways are solid double‑digit growth, improving profitability and a clear path toward stronger cash generation, tempered by reimbursement and execution risks that will require close monitoring.